Several mTOR inhibitors have already been approved for the therapeutic treatments of different types of cancer [276,277], while in neuroblastoma new clinical trials are ongoing (NCT02337309, NCT03213678) making mTOR inhibition a very promising therapeutic avenue for MYCN-deregulated childhood cancers (Table 3). This evidence concerns the gene MYCN and neuroblastoma.